NEW YORK (GenomeWeb News) – The University of Connecticut has inked a partnership with KeraFast to make stem cells developed at the university available globally.

KeraFast will market two stem cells lines created in 2009 from skin cells taken from patients with deletions of sections of chromosome 15 who develop Angelman Syndrome and Prader-Willi Syndrome. The stem cell lines were developed in the laboratories of UConn researchers Stormy Chamberlain and Marc Lalande.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.